WII 2002
Alternative Names: WII-2002Latest Information Update: 09 Aug 2021
At a glance
- Originator Whanin Pharmaceutical
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 20 Jul 2021 WII 2002 is available for licensing as of 19 Jul 2021. https://www.whanin.com/_commonBase/content.php?co_id=outlicense_kor# (Whanin Pharmaceutical Website, July 2021)
- 19 Jul 2021 Early research in Parkinson's disease in South Korea (unspecified route) before July 2021 (Whanin Pharmaceutical pipeline, July 2021)